ArticleEuropean heart journal. Acute cardiovascular care2024
Modelling costs of interventional pulmonary embolism treatment: implications of US trends for a European healthcare system.
Article in European heart journal. Acute cardiovascular care, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Impact of catheter-directed thrombolysis on the socio-economic burden of pulmonary embolism in Germany: a cost-effectiveness analysis.European heart journal. Quality of care & clinical outcomes · 2026Pooled it
- Advanced reperfusion therapies for acute pulmonary embolism in pregnancy and postpartum.European heart journal. Acute cardiovascular care · 2026Observational
- Pulmonary Embolism in the United States: A Report From the National PERT Consortium.Journal of the Society for Cardiovascular Angiography & Interventions · 2026Article
- Contemporary reperfusion therapies in patients with intermediate- and high-risk pulmonary embolism.Thrombosis research · 2025Article
- Drivers and recent trends of hospitalisation costs related to acute pulmonary embolism.Clinical research in cardiology : official journal of the German Cardiac Society · 2025Article
- Socioeconomic Burden of Pulmonary Embolism in Europe: Shifting Priorities and Challenges for Novel Reperfusion Strategies.Thrombosis and haemostasis · 2025Review
- Hospital Costs of Intracranial Haemorrhage in Patients with Acute Pulmonary Embolism: Possible Implications for Emerging Therapies.Thrombosis and haemostasis · 2025Article
- Time trends of catheter-directed treatment in acute pulmonary embolism in Germany.Research and practice in thrombosis and haemostasis · 2025Article
- Low-Dose Catheter-Directed Thrombolysis for Massive Pulmonary Embolism: A Case Report Highlighting Dosing Considerations in Asian Patients.Case reports in cardiology · 2025Article
- Article
- Review
- Intensive care treatment in acute pulmonary embolism in Germany, 2016 to 2020: a nationwide inpatient database study.Research and practice in thrombosis and haemostasis · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
aimsCatheter-directed treatment (CDT) of acute pulmonary embolism (PE) is entering a growth phase in Europe following a steady increase in the USA in the past decade, but the potential economic impact on European healthcare systems remains unknown. METHODS AND
resultsWe built two statistical models for the monthly trend of proportion of CDT among patients with severe (intermediate- or high-risk) PE in the USA. The conservative model was based on admission data from the National Inpatient Sample (NIS) 2016-20 and the model reflecting increasing access to advanced treatment from the PERT™ national quality assurance database registry 2018-21. By applying these models to the forecast of annual PE-related hospitalizations in Germany, we calculated the annual number of severe PE cases and the expected increase in CDT use for the period 2025-30. The NIS-based model yielded a slow increase, reaching 3.1% (95% confidence interval 3.0-3.2%) among all hospitalizations with PE in 2030; in the PERT-based model, increase would be steeper, reaching 8.7% (8.3-9.2%). Based on current reimbursement rates, we estimated an increase of annual costs for PE-related hospitalizations in Germany ranging from 15.3 to 49.8 million euros by 2030. This calculation does not account for potential cost savings, including those from reduced length of hospital stay.
conclusionOur approach and results, which may be adapted to other European healthcare systems, provide a benchmark for healthcare costs expected to result from CDT. Data from ongoing trials on clinical benefits and cost savings are needed to determine cost-effectiveness and inform reimbursement decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.